GlassScriptPhysician profile
Kim J Puckett
NPI 1154856466
$3,776.61
in general payments reported to CMS, 2019-2025
16 companies · $988 in 2025
The $988 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $681 · 2023: $739 · 2024: $1,098 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,278.37 | 2021-2025 | Ztlido |
| Forte Bio-Pharma LLC | $1,063.68 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $501.93 | 2023-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $266.64 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Vertex Pharmaceuticals Incorporated | $157.64 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $139.23 | 2021-2022 | |
| Biotronik Nro, INC. | $66.67 | 2023 | Biotronik |
| Abbott Laboratories | $58.88 | 2023-2024 | Proclaim |
| Redhill Biopharma INC. | $48.22 | 2021-2022 | |
| Spr Therapeutics, INC | $40.00 | 2022 | |
| Nevro Corp. | $33.05 | 2024 | Senza |
| Virtus Pharmaceuticals LLC | $32.70 | 2025 | Levorphanol Tartrate |
| Ibsa Pharma INC. | $27.49 | 2021-2023 | Tirosint, Licart |
| Biodelivery Sciences International, INC. | $23.86 | 2021 | |
| Lilly USA, LLC | $23.22 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.03 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Puckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.